We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nuformix plc (NFX) Ordinary 0.1p Shares

Sell:0.18p Buy:0.20p 0 Change: 0.07p (26.92%)
Market closed Prices as at close on 1 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.18p
Buy:0.20p
Change: 0.07p (26.92%)
Market closed Prices as at close on 1 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.18p
Buy:0.20p
Change: 0.07p (26.92%)
Market closed Prices as at close on 1 March 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nuformix plc is a United Kingdom-based pharmaceutical development company. The Company is engaged in targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its clinical pipeline includes NXP001, NXP002, and NXP004. NXP002 is its pre-clinical lead asset and a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and possibly other fibrosing interstitial lung diseases (ILDs). NXP001 is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy-induced nausea and vomiting). NXP004 is a form of Olaparib, which is used for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation.

Contact details

Address:
6th Floor, 60 Gracechurch Street
LONDON
EC3V 0HR
United Kingdom
Telephone:
+44 (01223) 627222
Website:
https://nuformix.com/

Important dates

Future events
AGM 19 March 2024 19/03/24
Past events
Annual report 15 January 2024 15/01/24
Final results 03 January 2024 03/01/24
AGM 24 August 2023 24/08/23

General stock information

EPIC:
NFX
ISIN:
GB00BYW79Y38
Market cap:
£1.49 million
Shares in issue:
744.31 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.